First-Line Combo Therapies Best Chemo Alone in Non-Small Cell Lung Cancer Trials Megan Brooks

https://www.medscape.com/viewarticle/first-line-combo-therapies-best-chemo-alone-non-small-cell-2026a1000ypv?src= New data from two phase 3 trials add complexity to the first-line treatment landscape for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions. In the final overall survival (OS) analysis of PAPILLON, which involved treatment-naive patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertions, those given amivantamab plus chemotherapy had a numerical improvement of 6.4 months over those who received chemotherapy alone.